C4 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	61.27	74.6	55.5	29.75	76.12	181.73
Short-Term Investments	174.4	173.93	189.41	246.4	233.16	189.96
Cash & Short-Term Investments	235.67	248.54	244.9	276.15	309.28	371.69
Cash Growth	-3.77%	1.48%	-11.32%	-10.71%	-16.79%	310.48%
Accounts Receivable	2.88	2.4	3.1	1.47	5.72	4.48
Other Current Assets	6.82	7.17	9.76	9.93	10.69	4.84
Total Current Assets	245.37	258.11	257.77	287.56	325.69	381.01
Net Property, Plant & Equipment	43.58	45.28	63.38	77.52	35.05	16.55
Long-Term Investments	32.6	48.56	22.36	60.96	142.2	-
Other Long-Term Assets	7.31	7.13	6.1	4.81	3.82	2.58
Total Assets	328.86	359.08	349.6	430.84	506.77	400.14
Accounts Payable	0.77	0.86	1.33	1.17	4.51	5.68
Accrued Expenses	9.83	13.31	19.36	19.77	13.61	9.52
Current Portion of Long-Term Debt	-	-	-	2.29	-	-
Current Portion of Leases	6.52	6.37	5.77	4.7	1.33	1.04
Unearned Revenue	10.12	12.49	18.71	16.62	31.8	27.6
Total Current Liabilities	27.25	33.03	45.18	44.55	51.25	43.85
Long-Term Debt	-	-	-	9.2	10.77	10.05
Long-Term Leases	51.93	53.62	59.98	70.97	30.78	11.83
Other Long-Term Liabilities	15.44	15.84	28.46	16.9	24.37	53.62
Total Long-Term Liabilities	67.37	69.46	88.44	97.06	65.91	75.5
Total Liabilities	94.61	102.49	133.62	141.61	117.16	119.35
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-in Capital	998.38	995.22	849.63	689.26	658.09	464.6
Accumulated Other Comprehensive Income	-0.32	0.05	0.05	-4.14	-0.78	0.01
Retained Earnings	-763.82	-738.69	-633.7	-395.89	-267.72	-183.82
Total Common Shareholders' Equity	234.25	256.59	215.99	289.23	389.61	280.79
Shareholders' Equity	234.25	256.59	215.99	289.23	389.61	280.79
Total Liabilities & Equity	328.86	359.08	349.6	430.84	506.77	400.14
Total Debt	58.45	59.98	65.76	87.15	42.88	22.92
Net Cash (Debt)	177.22	188.56	179.15	189	266.4	348.77
Net Cash Growth	-6.01%	5.25%	-5.21%	-29.05%	-23.62%	354.13%
Net Cash Per Share	1.83	2.27	2.58	3.87	5.79	30.67
Book Value	234.25	256.59	215.99	289.23	389.61	280.79
Book Value Per Share	2.43	3.10	3.11	5.92	8.46	24.70
Tangible Book Value	234.25	256.59	215.99	289.23	389.61	280.79
Tangible Book Value Per Share	2.43	3.10	3.11	5.92	8.46	24.70

SEC Filings: 10-K · 10-Q